Trump announces trade deal with EU following months of negotiations
PARIS - French biopharmaceutical company Inventiva (Euronext Paris and Nasdaq:IVA), currently valued at $456 million and maintaining impressive gross profit margins of 90%, announced Wednesday the appointment of Jason Campagna as President of Research and Development and Chief Medical Officer, and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance. According to InvestingPro analysis, the company appears overvalued at current levels.
Campagna, who previously served as Chief Medical Officer at Q32 Bio and as MASH Global Program Lead at Intercept Pharmaceuticals, succeeds company co-founder Pierre Broqua and outgoing CMO Michael Cooreman. Broqua will transition to a consulting role as Scientific Advisor.
Zimmermann joins from Ipsen where she led regulatory approvals for two liver disease drugs, including Iqirvo, a dual PPAR agonist for primary biliary cholangitis. She previously headed Global Regulatory Affairs & Quality at Alexion Pharma.
The leadership changes come as Inventiva advances its lead candidate lanifibranor, a pan-PPAR agonist being evaluated in the NATiV3 Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH). The company expects topline results from this pivotal study in the second half of 2026.
"Jason and Martine both bring exceptional leadership and experience during this pivotal time for the Company as we plan for the readout of our NATiV3 Phase 3 study next year and lanifibranor’s potential regulatory approval and commercialization," said Frederic Cren, CEO of Inventiva, in the press release.
Campagna noted his experience with MASH drug development, having led "the design and execution of one of the field’s most advanced clinical programs at Intercept—including the first-ever NDA submission in this indication."
Inventiva is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for MASH and other diseases with significant unmet medical needs.
In other recent news, Inventiva has announced the appointment of Renée Aguiar-Lucander to its Board of Directors. This move follows the company’s recent Annual General Meeting and aligns with the advancement of its lead drug candidate, lanifibranor, through late-stage clinical development. Aguiar-Lucander, who is currently the CEO of Hansa Biopharma, brings extensive experience from her previous role at Calliditas Therapeutics, where she led the company through significant growth and a $1.1 billion acquisition by Asahi Kasei. Additionally, Inventiva has outlined the terms of its share repurchase program, approved at the Ordinary General Meeting. The program allows the company to acquire up to 10% of its issued share capital over 18 months, with a maximum purchase price of 40 euros per share. The primary aim is to facilitate liquidity and market-making, with potential uses for employee stock option programs and capital reduction through share cancellation. These developments come as Inventiva continues to conduct a pivotal Phase 3 clinical trial for lanifibranor, targeting NASH, a chronic liver disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.